Lantern Pharma Inc.
General ticker "LTRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $41.5M (TTM average)
Lantern Pharma Inc. follows the US Stock Market performance with the rate: 31.1%.
Estimated limits based on current volatility of 4.2%: low 3.47$, high 3.78$
Factors to consider:
- Total employees count: 60 (+160.9%) as of 2023
- Top business risk factors: Regulatory and compliance, Product development delays, Limited operating history, Transition to commercialization, Operational and conduct risks
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.19$, 5.42$]
- 2024-12-30 to 2025-12-30 estimated range: [1.82$, 4.61$]
Financial Metrics affecting the LTRN estimates:
- Positive: with PPE of -2.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -31.93 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: -4.48 < Investing cash flow per share per price, % of -2.07
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -22.08 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term LTRN quotes
Long-term LTRN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.59MM | $14.43MM | $17.88MM |
| Operating Income | $-12.59MM | $-14.43MM | $-17.88MM |
| Non-Operating Income | $0.07MM | $0.17MM | $1.92MM |
| R&D Expense | $7.57MM | $8.60MM | $11.89MM |
| Income(Loss) | $-12.52MM | $-14.26MM | $-15.96MM |
| Profit(Loss)* | $-12.36MM | $-14.26MM | $-15.96MM |
| Stockholders Equity | $71.57MM | $56.04MM | $40.91MM |
| Assets | $73.95MM | $58.84MM | $43.65MM |
| Operating Cash Flow | $-10.59MM | $-12.77MM | $-14.35MM |
| Capital expenditure | $0.02MM | $0.03MM | $0.02MM |
| Investing Cash Flow | $-19.53MM | $0.18MM | $-0.93MM |
| Financing Cash Flow | $63.42MM | $-2.18MM | $-0.50MM |
| Earnings Per Share** | $-1.13 | $-1.31 | $-1.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.